Hospital
Medical University Hospital Authority
Medical University Hospital Authority was paid $6.98M by Medicaid between Aug 2021 and Dec 2024, across 178 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 20% of everything it billed.
33Billing provider infoMEDICAL UNIVERSITY HOSPITAL AUTHORITY
CAMDEN, SC 29020
CAMDEN, SC 29020
33aNPI1487220307assigned 06/01/2021
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.98M
24GClaims229,185
24DCodes billed178
24AFirst – last monthAug 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#44 of 115
Median peer was paid$2.47M
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RAE, KARYN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 26,143 | $1.20M | |
| 2022 | 67,239 | $2.01M | |
| 2023 | 70,849 | $2.13M | |
| 2024incomplete | 64,954 | $1.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 20% | 9,584 | 9,166 | $1.43M |
| 80053 | Comprehensive metabolic panel | 15% | 12,953 | 11,070 | $1.03M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.6% | 4,077 | 3,887 | $530K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 6.3% | 2,819 | 2,469 | $443K |
| 36415 | Collection of venous blood by venipuncture | 5.5% | 14,956 | 11,603 | $383K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.7% | 11,434 | 10,672 | $260K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.6% | 4,260 | 3,532 | $248K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.2% | 1,695 | 1,635 | $152K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.8% | 1,437 | 1,320 | $123K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 2,474 | 1,983 | $121K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 3,272 | 935 | $111K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.3% | 4,204 | 3,880 | $91K |
166 more codes
| 81025 | 1.3% | 4,317 | $89K | |
| 81001 | 1.3% | 7,215 | $88K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 4,716 | $78K |
| 81003 | 1.1% | 3,210 | $76K | |
| 87081 | 1.0% | 549 | $71K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,330 | $68K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 418 | $67K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,986 | $65K |
| 73610 | <1% | 816 | $64K | |
| 86850 | <1% | 678 | $63K | |
| 82947 | <1% | 1,464 | $59K | |
| 99284 | Emergency room visit (serious) | <1% | 7,358 | $58K |
| 73130 | <1% | 552 | $56K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,073 | $55K |
| 87077 | <1% | 1,592 | $53K | |
| 73630 | <1% | 923 | $52K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,965 | $49K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,321 | $42K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,894 | $40K |
| 73562 | <1% | 742 | $39K | |
| 86900 | <1% | 857 | $39K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 913 | $36K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 805 | $35K |
| 84702 | <1% | 1,217 | $35K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,363 | $35K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 288 | $33K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 462 | $32K |
| 73030 | <1% | 646 | $30K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,712 | $30K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,754 | $28K |
| 87210 | <1% | 425 | $27K | |
| 88304 | <1% | 154 | $26K | |
| 73110 | <1% | 381 | $26K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 491 | $24K |
| 99285 | Emergency room visit (most serious) | <1% | 4,114 | $24K |
| 74018 | <1% | 510 | $21K | |
| 72100 | <1% | 515 | $20K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 468 | $19K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 142 | $17K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 175 | $16K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,195 | $13K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 29 | $13K |
| 80061 | Lipid panel | <1% | 2,371 | $13K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,150 | $12K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 355 | $12K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 151 | $12K |
| 85027 | <1% | 3,665 | $10K | |
| 84439 | <1% | 863 | $9K | |
| 97161 | <1% | 287 | $9K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 15 | $8K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 27 | $7K |
| 87807 | <1% | 196 | $7K | |
| 83735 | <1% | 3,498 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 778 | $7K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,245 | $7K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 122 | $7K |
| 82728 | <1% | 546 | $6K | |
| 82607 | <1% | 549 | $5K | |
| 59025 | Fetal non-stress test | <1% | 319 | $5K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $5K |
| G0378 | Hospital observation service, per hour | <1% | 587 | $5K |
| 85007 | <1% | 1,159 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,028 | $5K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 32 | $4K |
| 93971 | <1% | 15 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,630 | $4K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,586 | $4K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,523 | $3K |
| 85610 | <1% | 1,055 | $3K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 574 | $3K |
| 31231 | <1% | 14 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 629 | $3K |
| 72040 | <1% | 31 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,832 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 765 | $3K |
| 84550 | <1% | 70 | $3K | |
| 73140 | <1% | 13 | $2K | |
| 86140 | <1% | 457 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 511 | $2K |
| 83690 | <1% | 2,340 | $2K | |
| 76775 | <1% | 29 | $2K | |
| 71250 | <1% | 12 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 111 | $2K |
| 73560 | <1% | 12 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 379 | $2K |
| 73502 | <1% | 125 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 230 | $2K |
| 82550 | <1% | 607 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 12 | $2K |
| 96376 | <1% | 660 | $2K | |
| 93017 | <1% | 83 | $1K | |
| 84153 | <1% | 55 | $1K | |
| 36600 | <1% | 21 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 654 | $1K |
| 83540 | <1% | 672 | $1K | |
| 84145 | <1% | 464 | $1K | |
| 73090 | <1% | 37 | $911.69 | |
| 82570 | <1% | 432 | $770.44 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,577 | $764.90 |
| 85379 | <1% | 158 | $706.77 | |
| 84484 | <1% | 3,977 | $680.06 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 790 | $651.09 |
| 80143 | <1% | 288 | $549.63 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 80 | $544.03 |
| 73590 | <1% | 26 | $497.55 | |
| 72070 | <1% | 13 | $406.53 | |
| 82746 | <1% | 324 | $382.04 | |
| 82247 | <1% | 19 | $327.10 | |
| 71100 | <1% | 12 | $266.64 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 91 | $240.52 |
| 74019 | <1% | 15 | $215.51 | |
| 86038 | <1% | 26 | $187.09 | |
| 82803 | <1% | 82 | $79.15 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 870 | $75.00 |
| 85652 | <1% | 432 | $55.02 | |
| 83880 | <1% | 979 | $53.51 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 28 | $39.82 |
| 87040 | <1% | 824 | $25.81 | |
| 84132 | <1% | 15 | $24.89 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,856 | $22.87 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 363 | $19.15 |
| 80179 | <1% | 282 | $14.91 | |
| 82077 | <1% | 695 | $13.82 | |
| 85046 | <1% | 120 | $6.13 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 743 | $5.26 |
| 84156 | <1% | 239 | $4.82 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,141 | $3.06 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,411 | $0.94 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,307 | $0.85 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 151 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 27 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 78 | $0.00 |
| 84100 | 0% | 372 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 63 | $0.00 |
| 85045 | 0% | 100 | $0.00 | |
| 90715 | 0% | 64 | $0.00 | |
| 87186 | 0% | 1,081 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 103 | $0.00 |
| 82248 | 0% | 42 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 22 | $0.00 |
| 83970 | 0% | 72 | $0.00 | |
| 82565 | 0% | 14 | $0.00 | |
| 84295 | 0% | 14 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 72 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 26 | $0.00 |
| 84520 | 0% | 14 | $0.00 | |
| 82310 | 0% | 14 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 986 | $0.00 |
| A9270 | Non-covered item or service | 0% | 396 | $0.00 |
| 86901 | 0% | 858 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 89 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,032 | $0.00 |
| 83605 | 0% | 1,410 | $0.00 | |
| 85730 | 0% | 284 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 305 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 381 | $0.00 |
| 80329 | 0% | 69 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 90 | $0.00 |
| 83550 | 0% | 294 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 63 | $0.00 |
| 80320 | 0% | 181 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 17 | $0.00 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 69 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 27 | $0.00 |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 13 | $0.00 |
| 82435 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRAE, KARYN (CHAIR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.